VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has filed a pre-IND (Investigational New Drug) meeting request with the U.S. FDA for its investigation of AP-188 (“N,N-Dimethyltryptamine or DMT”)…


Previous articleOptimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch
Next articleCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study